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Abstract
Benign familial hematuria (BFH) is characterized by auto­
somal dominant inheritance, thinning of the glomerular 
basement membrane (GBM) and normal renal function. It 
is frequent in patients with persistent microscopic hema­
turia, but cannot be clinically differentiated from the initial 
stages of Alport syndrome, a severe GBM disorder which 
progresses to renal failure. We present here linkage of be­
nign familial hematuria with the COL4A3 and COL4A4 
genes at 2q35-37 (Zmax = 3.58 at 0 = 0.0). Subsequently, a 
glycine to glutamic acid substitution was identified in the 
collagenous region of the COL4A4 gene. We conclude that 
type IV collagen defects cause both benign hematuria and 
Alport syndrome. Furthermore, our data suggest that BFH 
patients can be carriers of autosomal recessive Alport syn­
drome. (J. Clin. Invest 1996. 98:1114-1118.) Key words: he­
maturia • Alport syndrome • basement membrane * collagen
• mutation analysis
Introduction
Hematuria is the presenting symptom in a large number of re­
nal disorders. If the hematuria occurs in childhood, is isolated
and is of glomerular origin, die diagnosis is difficult to reach. 
Benign hematuria, Alport syndrome and IgA-nephropathy all 
present with persistent hematuria. Particularly, differentiation 
between Alport syndrome, which is a severe renal disorder, 
progressing to renal failure in most cases, and benign hema­
turia is mandatory for correct prediction of prognosis and ge­
netic counseling. In benign hematuria electron microscopic 
analysis of renal biopsies shows thinning of the glomerular 
basement membrane (GBM )1 (1-3), while in Alport syndrome
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renal biopsies are characterized by irregular thickening and 
multilamination of the GBM (4). However, thinning of the 
GBM may be the only microscopic abnormality in younger 
Alport patients (5-7), which hampers the differentiation be­
tween the two disorders in childhood. Renal biopsies of 65 
children with isolated hematuria persisting for at least one year 
revealed histological abnormalities consistent with Alport syn­
drome in eight cases and consistent with benign hematuria in 
33 cases (3). A positive family history was detected in 23 of the 
33 cases.
The major structural component of the GBM is formed by 
a type IV collagen network. As yet, six different type IV col­
lagen chains have been identified and the respective genes 
were cloned. Mutations were detected in three type IV col­
lagen genes in Alport syndrome, The majority was present in 
the X-linked type IV collagen a5 (COL4A5) gene, but re­
cently mutations in the type IV collagen a3 and a4 (COL4A3/ 
A4) genes have been reported in patients with the autosomal 
recessive form of this disease (8, 9), These tatter two collagen 
genes are localized head to head on the tip of the long arm of 
chromosome 2 (10). Considering the similarities in GBM ab­
normalities, autosomal Alport syndrome and BFH could be 
the severe and mild forms of different molecular genetic de­
fects in the same genes. Here we report linkage of the 
COL4A3/A4 locus to BFH in a large Dutch family (11) and 
the identification of a pathogenic mutation in the COL4A4 
gene.
Methods
Patients. The index patient (111:10; see Fig. 1 ) presented with hema­
turia at the age of 5 years. There were no concomitant abnormalities, 
i.e., glomerular filtration rate was normal and hypercalciuria was ab­
sent. There was also no hypertension. The morphology of the eryth­
rocytes in the urinary sediment indicated a glomerular origin of the 
cells. Audiography and fundoscopy revealed no abnormalities. Fam­
ily history was negative for renal failure and deafness. One year later 
a renal biopsy was performed. Electron microscopy of the biopsy 
specimen showed regions with malformations of the glomerular base­
ment membrane, typical for Alport syndrome, and regions which 
were thin. Further investigation of the family showed microscopic he­
maturia in both parents and his younger brother (111:1 1 ), but no other 
symptoms suggestive for Alport syndrome. Renal function was nor­
mal in the parents (11:7 and 11:8; normal serum creatinine concentra­
tion). Microscopic hematuria was present in three sisters of the father 
(11:7) and in half of their off-spring, as well as in the grandfather (1:1 ; 
Fig. 1). Particularly important is that this 75-yr-oId man had a normal 
serum creatinine concentration. In the family of the mother (11:8) he­
maturia was also widely present. Her 76-yr-old father had hematuria 
and a normal creatinine level, her mother was healthy. It was con-
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eluded that the family history on both sides strongly supported the di­
agnosis BFH. The index patient might have inherited the disorder 
form both parents, which could explain the aberrant morphology of 
the biopsy specimen. He is presently 16 years old and symptoms are 
hematuria and recently developed proteinuria (0.5 grams/liter). He­
maturia was defined as a condition with 10 or more erythrocytes per 
mm3 urine, established by the quantitative sediment method of Gade- 
holt (12). Individuals with borderline values were repeatedly ana­
lyzed. All family members could unambiguously be scored as either 
affected or unaffected.
Linkage analysis. Blood samples were collected from family 
members and genomic DNA was isolated by a salting out procedure 
(13). The COL4A3/COL4A4 CA repeat was PCR amplified using 
125 ng of primers CAI IF (5'-ATC TCT CAG GGT GCG TGC-3') 
and CA11R (5'-CTC ATT GAT ACA CAC A A A  TGC A-3') and 
50-100 ng DNA template in a standard Cetus buffer with 2 mM 
MgCl2. After 3 min at 94°C, four initial cycles were performed of 1 min 
at 94°C, 1 min at 58°C and I min at 72°C followed by 30 cycles of 1 
min at 94QC, 1 min at 55°C and 1 min at 72°C. One of the primers was 
fluorescently labeled and the PCR product was analyzed on an ABf 
373A Automated Sequencer using the Genescan software package 
(Applied Biosystems, Foster City, CA). A  COL4A4 Haelll RFLP 
was identified by SSCP and subsequent sequence analysis and is 
caused by a neutral mutation at the J198glycine residue of the 
COL4A4 gene. PCR was performed on 100 ng genomic DNA using 
100 ng of intronic oligonucleotides A41F10 (5'-AGGCACTATAAC- 
AGGGACAAGA-3') (9) and 714 (5'-CCTCATTGCATTTGGAAG- 
GT-3'), 200 jjlM  dNTPs, 5% DMSO in Ampli-Taq buffer containing 
67 mM Tris-HCl (pH = 8.8), 16.6 mM (NT-ySO,,, 6.7 mM MgCU, 0.17 
mg/ml BSA (Boehringer Mannheim, Germany) to a total volume of 
25 julI. The sequence of oligo 714 is the reverse of oligonucleotide 
A41F9 (9). After 5 min of dénaturation at 96°C 1 U Ampli-Taq DNA 
polymerase (Perkin-Elmer, Norwalk, CT) was added ancl 30 cycles of 
PCR were started (dénaturation at 94°C for 1 min, annealing at 62°C 
for I min and extension at 72°C for 1 min and 30 s). if the Haelll site 
is present, digestion of the PCR fragment (260 bp) gives two bands of 
182 and 78 bp (data not shown).
Two point and multi-point lod scores were calculated using the 
MLINK and LINICMAP options of the L INKAGE package com­
puter program (version 5.03) (14). BFH was defined as an autosomal 
dominant disorder with complete penetrance. The disease frequency 
was estimated to be 0.0001.
Mutation analysis. RN A  was isolated from peripheral blood 
lymphocytes (PBL) or EBV transformed PBL from affected and nor­
mal individuals by RNAzol extraction (15). COL4A3 and COL4A4 
cDNA fragments were generated by RT-PCR analysis as described 
before (8, 16). Oligonucleotides were designed to amplify COL4A3 
and COL4A4 cDNA by multiple overlapping cDNA fragments. 
D N A  fragments were sequenced on an AB I 373A automated se­
quencer. Reaction conditions using dyedeoxy''^-terminators were ac­
cording to a protocol provided by the manufacturer (Applied Biosys­
tems, Foster City, CA). The GIy897Glu mutation was identified in 
the PCR fragment, flanked by outer primers 945 (5'-GCGAAG- 
G GTG A CAT G GTT G T ATC A  -3 ' ) starting at position 1871 and 946 
(5'-CCTCTC A G  A AG  GTC A  ACACTCCCAG -3' ) starting at position 
4074 (17) in a first round of 35 cycles; dénaturation for 1 min at 92°C, 
î min 30 s of annealing at 60°C and extension for 3 min at 72°C. Two 
microliters out of the first PCR reaction was used as template for a 
second round of 35 cycles using inner primers FlOO (5'-AAGGCC- 
TCCCCGGACTCCCA-3') at position 2750 and R101 (S'-CGGGAG- 
GTCCTATGGCTC-3') at position 3017 (17); dénaturation for 1 min 
at 92°C, 1 min 30 s of annealing at 55°C and extension for 2 min at 
72°C. The GJy897Glu mutation created an A lul restriction site and 
was screened at the genomic D N A  level by PCR amplification using 
oligonucleotides F100 (5'-AAGGCCTCCCCGGACTCCCA-3') and 
1106 (5'-ACCTGGAGGACCAGGTAGC-3') and digestion with
A lul restriction enzyme (G IBCO  BRL, Gaithersburg, M D). If the 
mutation is present the 104-bp PCR fragment is cleaved in two frag­
ments of 86 and 18 bp. The smallest fragment is not visible.
Results
Linkage analysis. Linkage analysis was performed with two 
novel polymorphic markers from the COL4A3/COL4A4 lo­
cus. The most informative marker was a CA repeat, isolated 
from a YAC  clone with an insert of 540 kb, containing both 
COL4A3 ancl COL4A4 genes (18). The other marker was a
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Figure /. Segregation analysis of type IV collagen a3 and a4 markers in the BFH family. Haplotypes were constructed for the type IV collagen 
tt3/c¿4 CA repeat and the type IV collagen a4 Haelll RFLP. Type IV collagen a3/a4 CA  repeat fragments are indicated as the length of the PCR 
fragment in basepairs (76,78, and 80 bp). The Haelll RFLP alleles are represented by 1 (Haelll site absent) and 2 (Haelll site present). The 
haplotype [78,2], shown as black bars, cosegregates with BFH, Filled symbols indicate individuals with hematuria. Arrow indicates index patient
(III-10).
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Figure 2. Gly897Glu substitu­
tion in the type IV collagen a4 
chain in BFH. Sequence analysis 
of type IV collagen a4 cDNA of 
the index patient and a normal 
control. The mutation, which 
changes the glycine (G) codon 
897 GGG into the glutamic acid 
(E) codon GAG  is indicated by 
an arrow. Type IV collagen 
chains consist of collagenous 
and nou-collagenous (NC) do­
mains. Three type IV collagen 
chains form a triple helix, which
r
of a conserved glycine residue.
Haelll RFLP in one of the exons of the COL4A4 gene. Be­
cause the genomic structure of COL4A4 is not clarified yet, 
the exact numbering of exons is unknown, but most likely exon 
8 is involved (counting from the 3' end). The RFLP is caused
by a polymorphism, a neutral G to A nucleotide substitution at
this polymorphism were 0.5/0.5 (70 unrelated individuals 
tested).
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Figure 3. Segregation of GIy897Glu 
mutation in the BFH family. The 
presence of the mutation creates an 
additional Alul restriction site. 
Cleavage of the 104 bp PCR frag­
ment in two shorter fragments of 86 
and 18 basepairs is indicative for the 
presence of the mutation. Only the 
affected family members {filled sym­
bols) show the shorter DNA frag-
*ÍUT
of 18 bp is not visible. DNA fragment 
lengths are indicated in basepairs 
(bp ) .
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Linkage analysis was performed in the paternal (11:7) side 
of the pedigree (Fig. 1). The mother (11:8) and her two sons, 
111:10 and 111:11 (Fig. 1), were not included in the linkage stud­
ies, because BFH segregated also in the maternal line. The 
maternal relatives were not available for linkage analysis. A  
maximum lod score (Zmax) of 3.01 was obtained in the paternal 
(11:7; Fig. 1) line with the COL4A3/COL4A4 CA repeat at re­
combination fraction (0) of 0.0 in our family. The Zmux ob­
tained with the intragenic COL4A4 RFLP is 1.51 at 0  — 0.0. 
All affected individuals share the haplotype [78, 2] for both 
markers (Fig. 1). This haplotype was linked to BFH with a
Zmnx of 3.58 at 0  = 0.0.
Mutation analysis. RT-PCR was performed on total lym­
phocyte RNA followed by direct sequence analysis of ampli­
fied COL4A3 and COL4A4 cDNA fragments. A heterozy­
gous G to A nucleotide substitution was identified at position 
2898 of the COL4A4 gene in the patients 111:10 and 111:11 and 
in their father 11:7, but not in their mother 11:8. The glycine 
codon GGG at position 897 was changed into GAG, encoding 
a glutamic acid residue (Fig. 2). The mutation introduced a 
novel site for the restriction enzyme Alul and the other family 
members and controls were screened for the presence of this 
site. If the Alul site is present, a 104 bp PCR fragment will be 
cleaved in two smaller fragments of 86 and 18 bp (Fig. 2). All 
affected family members were heterozygous for the mutation 
(Fig. 3) and the mutation was not detected in the unaffected 
family members and 50 unrelated controls (data not shown).
drome. This is in line with the histological examination of the 
kidney biopsy and the presence of proteinuria in the index pa­
tient, who is a suspected compound BFH heterozygote. The 
definite proof awaits the detection of the second maternal 
BFH mutation and the progression of his renal disease.
In conclusion, this is the first report on a genetic defect ex­
plaining benign hematuria. The identification of type IV col­
lagen defects, similar to those found in Alport syndrome, is im­
portant for genetic counseling and prognostic prediction. As 
yet, this prediction can not be based on the mutation only, but 
needs a compiete investigation of family history, follow-up ex­
amination and renal biopsy. In a recent report linkage of the 
rare autosomal dominant form of Alport syndrome to the type 
IV collagen a3 and a4 locus was demonstrated in a large 
Northern-Irish family (Jefferson, J.A., A.P. Maxwell, A.E. 
Hughes, C.M. Hill, C.C. Doherty, and N.C. Nevin. Autosomal 
dominant Alport syndrome linked to the type IV collagen o¿3 
and a4 genes (COL4A3 and COL4A4), manuscript submitted 
for publication). It is obvious that the type IV collagen a3 and 
cx4 genes are strong candidates for the autosomal dominant 
form of Alport syndrome as well. This would complete the 
spectrum of phenotypes of type IV  collagen o¿3 and u.4 defects, 
ranging from neutral amino acid substitutions (8) and benign 
hematuria to mild autosomal dominant and severe recessive 
Alport syndrome. In this way, the type IV collagen mutations 
fit within the rule of extreme clinical and genetic variability of 
collagen disorders (21).
Discussion
For several reasons, the Gly897Glu mutation in the type IV 
collagen o¿4 chain is likely to be the pathogenic mutation in the 
BFH family. First, the mutation changes a glycine in a con­
served collagenous triple helical domain in the type IV col­
lagen a4 chain (17). Every third amino acid is a glycine, be­
cause it is the only residue small enough to fit into the center of 
the triple helical molecule (19). If glycine residues are substi­
tuted by bulkier amino acids such as glutamic acid the triple 
helix structure will be distorted (Fig. 2). Unlike fibrillar col- 
lagens, type IV collagen triple helices contain 21-26 interrup­
tions, which are assumed to provide flexibility to the molecule. 
However, the positions of these interruptions are highly con­
served during evolution and the generation of an additional in­
terruption may interfere with correct folding of the intricate 
type IV collagen tri mers, consisting of type IV collagen ct3, c¿4, 
and c¿5 chains. Substitutions for glycines in the collagenous tri­
ple helical domain are also a common cause of other collagen 
disorders, like osteogenesis imperfecta and Ehlers D anlos syn­
drome (20). Furthermore, the mutation cosegregates with 
BFH in our family and, finally, the mutation is absent from a 
control group of 50 individuals, which provides additional evi­
dence for the pathogenicity of the defect.
In 1994, homozygous mutations in the type IV collagen tx3 
and a4 genes have been identified in patients with autosomal 
recessive Alport syndrome (8, 9). Two different mutations 
were reported in the type IV collagen c¿4 gene: a glycine to 
serine substitution and a serine to stop mutation (9). Similar to 
the Gly897Glu mutation in the BFH family presented here, 
the glycine is substituted in the triple helical domain of the 
type IV collagen a4 chain. Our data suggest that BFH patients 
can be manifesting carriers of autosomal recessive Alport syn-
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